Vitamin E Supplementation and Cataract: Randomized Controlled Trial

Ophthalmology

Volumn 111, Issue 1, 2004, Pages 75-84

  McNeil, John J ^a,d   Robman, Luba ^b   Tikellis, Gabriella ^b   Sinclair, Martha I ^a   McCarty, Catherine A ^b,c   Taylor, Hugh R ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MARSHFIELD CLINIC   (United States)

^d The Alfred   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; PLACEBO;

ADULT; AGED; AGING; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; EYE DISEASE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0346157377     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2003.04.009     Document Type: Article

References (55)

1. Age-Related Eye Disease Study Group. Risk factors associated with age-related nuclear and cortical cataract: a case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5. Ophthalmology 2001;108:1400-8.
2. McCarty CA, Nanjan MB, Taylor HR. Attributable risk estimates for cataract to prioritize medical and public health action. Invest Ophthalmol Vis Sci 2000;41:3720-5.
3. Taylor HR. Epidemiology of age-related cataract. Eye 1999;13:445-8.
4. Leske MC, Chylack LT Jr, He Q, et al. Risk factors for nuclear opalescence in a longitudinal study. LSC Group. Longitudinal Study of Cataract. Am J Epidemiol 1998;147:36-41.
5. Hiller R, Sperduto RD, Podgor MJ, et al. Cigarette smoking and the risk of development of lens opacities. The Framingham studies. Arch Ophthalmol 1997;115:1113-8.
6. West SK, Valmadrid CT. Epidemiology of risk factors for age-related cataract. Surv Ophthalmol 1995;39:323-34.
7. Flaye DE, Sullivan KN, Cullinan TR, et al. Cataracts and cigarette smoking. The City Eye Study. Eye 1989;3:379-84.
8. West S. Ocular ultraviolet B exposure and lens opacities: a review. J Epidemiol 1999;9(suppl):S97-101.
9. Taylor HR. Ultraviolet radiation and the eye: an epidemiologic study. Trans Am Ophthalmol Soc 1989;87:802-53.
10. Skalka HW, Prchal JT. Effect of corticosteroids on cataract formation. Arch Ophthalmology 1980;98:1773-7.
11. Shui YB, Vrensen GF, Kojima M. Experimentally induced steroid cataract in the rat: a scanning electron microscopic study. Surv Ophthalmol 1997;42(suppl 1):S127-32.
12. Dickerson JE Jr, Dotzel E, Clark AF. Steroid-induced cataract: new perspective from in vitro and lens culture studies. Exp Eye Res 1997;65:507-16.
13. Varma SD, Srivastava VK, Richards RD. Photoperoxidation in lens and cataract formation: preventive role of superoxide dismutase, catalase and vitamin C. Ophthalmic Res 1982;14(3):167-75.
14. Fecondo JV, Augusteyn RC. Superoxide dismutase, catalase and glutathione peroxidase in the human cataractous lens. Exp Eye Res 1983;36:15-23.
15. McNamara M, Augusteyn RC. The effects of hydrogen peroxide on lens proteins: a possible model for nuclear cataract. Exp Eye Res 1984;38:45-56.
16. Dudek EJ, Shang F, Taylor A. H(2)O(2)-mediated oxidative stress activates NF-kappa B in lens epithelial cells. Free Radic Biol Med 2001;31:651-8.
17. Boscia F, Grattagliano I, Vendemiale G, et al. Protein oxidation and lens opacity in humans. Invest Ophthalmol Vis Sci 2000;41:2461-5.
18. Ottonello S, Foroni C, Carta A, et al. Oxidative stress and age-related cataract. Ophthalmologica 2000;214:78-85.
19. Taylor A, Nowell T. Oxidative stress and antioxidant function in relation to risk for cataract. Adv Pharmacol 1997;38:515-36.
20. Ohta Y, Torii H, Okada H, et al. Involvement of oxidative stress in D-xylose-induced cataractogenesis in cultured rat lenses. Curr Eye Res 1996;15:1-7.
21. Spector A. Oxidative stress-induced cataract: mechanism of action. FASEB J 1995;9:1173-82.
22. Wang K, Spector A. Alpha-crystallin can act as a chaperone under conditions of oxidative stress. Invest Ophthalmol Vis Sci 1995;36:311-21.
23. Bender CJ. A hypothetical mechanism for toxic cataract due to oxidative damage to the lens epithelial membrane. Med Hypotheses 1994;43:307-11.
24. Duncan G, Wormstone IM, Davies PD. The aging human lens: structure, growth, and physiological behaviour. Br J Ophthalmol 1997;81:818-23.
25. Harding J. Cataract. Biochemsitry, Epidemiology and Pharmacology. London: Chapman and Hall; 1991:382.
26. Trevithick JR, Mitton KP. Vitamins C and E in cataract risk reduction. Int Ophthalmol Clin 2000;40:59-69.
27. Kojima M, Shui YB, Murano H, Sasaki K. Inhibition of steroid-induced cataract in rat eyes by administration of vitamin-E ophthalmic solution. Ophthalmic Res 1996;28:64-71.
28. Wu SY, Leske MC. Antioxidants and cataract formation: a summary review. Int Ophthalmol Clin 2000;40(4):71-81.
29. Jacques PF, Chylack LT Jr, Hankinson SE, et al. Long-term nutrient intake and early age-related nuclear lens opacities. Arch Ophthalmol 2001;119:1009-19.
30. Kuzniarz M, Mitchell P, Cumming RG, Flood VM. Use of vitamin supplements and cataract: the Blue Mountains Eye Study. Am J Ophthalmol 2001;132:19-26.
31. Jacques PF, Taylor A, Hankinson SE, et al. Long-term vitamin C supplement use and prevalence of early age-related lens opacities. Am J Clin Nutr 1997;66:911-6.
32. Mares-Perlman JA, Brady WE, Klein BE, et al. Diet and nuclear lens opacities. Am J Epidemiol 1995;141:322-34.
33. Seddon JM, Christen WG, Manson JE, et al. The use of vitamin supplements and the risk of cataract among US male physicians. Am J Public Health 1994;84:788-92.
34. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001;119:1439-52.
35. Garrett SK, McNeil JJ, Silagy C, et al. Methodology of the VECAT Study: vitamin E intervention in cataract and age-related maculopathy. Ophthalmic Epidemiol 1999;6:195-208.
36. Taylor HR, Tikellis G, Robman LD, et al. Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ 2002;325:11-4.
37. Taylor HR, West SK. A simple system for the clinical grading of lens opacities. Lens Res 1988;5:175-81.
38. Bailey IL, Bullimore MA, Raasch TW, Taylor HR. Clinical grading and the effects of scaling. Invest Ophthalmol Vis Sci 1991;32:422-32.
39. Robman LD, McCarty CA, Garrett SKM, et al. Variability in digital assessment of cortical and posterior subcapsular cataract. Ophthalmic Res 1999;31:110-8.
40. Robman L, McCarty CA, Garrett SKM, et al. Comparison of clinical and digital assessment of nuclear optical density. Ophthalmic Res 1999;31:119-26.
41. Garrett S, Robman LD, McCarty CA, et al. Reproducibility of automatic standard digital analysis of lens opacities. Aust N Z J Ophthalmol 1998;26(suppl 2):S29-31.
42. Robman LD. Measurement of change in lens opacities over 2 years with the Nidek EAS-1000 image analysis system [dissertation]. Melbourne, Australia: University of Melbourne; 2000:182.
43. Nidek Anterior Eye Segment Analysis System: EAS-1000. Operator's Manual. Japan: Nidek Co., Ltd.; 1991:71.
44. West S, Munoz B, Schein OD, et al. Cigarette smoking and risk for progression of nuclear opacities. Arch Ophthalmol 1995;113:1377-80.
45. Rothman KJ. "Episheet" epidemiologic software. Available at: http://members.aol.com/krothman/episheet.xls. Accessed October 6, 2002.
46. McCarty CA, Mukesh BN, Dimitrov PN, Taylor HR. The incidence and progression of cataract in the Melbourne Visual Impairment Project. Am J Ophthalmol 2003;136:10-7.
47. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000;342:154-60.
48. Lonn E, Yusuf S, Dzavik V, et al, SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25.
49. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55.
50. Gey KF. Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofactors 1998;7:113-74.
51. Weinberg RB, VanderWerken BS, Anderson RA, et al. Prooxidant effect of vitamin E in cigarette smokers consuming a high polyunsaturated fat diet. Arterioscler Thromb Vasc Biol 2001;21:1029-33.
52. Azzi A, Breyer I, Feher M, et al. Specific cellular responses to alpha-tocopherol. J Nutr 2000;130:1649-52.
53. Stocker R. The ambivalence of vitamin E in atherogenesis. Trends Biochem Sci 1999;24:219-23.
54. Yamashita N, Murata M, Inoue S, et al. Alpha-tocopherol induces oxidative damage to DNA in the presence of copper(II) ions. Chem Res Toxicol 1998;11:855-62.
55. Bagnati M, Perugini C, Cau C, et al. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999;340(Pt 1):143-52.